In addition, IL-33-neutralizing antibody wasinjected into tumor-bearing mice to further clarify its roles on CRC development, andresults showed that neutralization of IL-33 significantly decreased serum levels of IL-33and tumor size (Figure 4A),dampened Treg and ST2L+Treg cells in tumor-bearing mice (Figure 4B-E) as well as decreased antiinflammatoryfactors (Figures 4F-5H). The gene discussed is IL33; the disease is neoplasm.